Merck KGaA and GlaxoSmithKline have seen their ambition to expand in oncology badly dented by the failure of a key Phase III lung cancer trial.
Bintrafusp alfa is one of the most important assets for both companies, but the INTR@PID Lung 037 trial in non-small...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
